Research Topics
| SEBASTIAN G SCHNEEWEISSSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritisSeo Young Kim
Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
Arthritis Res Ther 12:R154. 2010..Although osteoporosis has been reported to be more common in patients with rheumatoid arthritis (RA), little is known whether the risk of osteoporotic fractures in these patients differs by age, sex, and anatomic site...- The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28Masayo Sato
Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
Arthritis Res Ther 8:R57. 2006..The RARBIS has both face and convergent validity for patients with RA and relevant subgroups and may have application for medical records studies in patients with RA... - Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary studyGladys Ting
Department of Medicine, Division of Pharmacoepidemiology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
Arthritis Res Ther 10:R95. 2008.... - The effect of Medicare Part D coverage on drug use and cost sharing among seniors without prior drug benefitsSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women s Hospital in Boston, Massachusetts, USA
Health Aff (Millwood) 28:w305-16. 2009..Patients reaching the Part D coverage gap (12 percent) experienced a decrease in essential medication use ranging from 5.7 percentage points per month for warfarin to 6.3 percentage points for statins... 
Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experimentSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, MA 02120, USA
Circulation 115:2128-35. 2007....- Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry dataSoko Setoguchi
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
Cancer Causes Control 18:561-9. 2007..However, linkage between cancer registry and claims data including pharmacy-dispensing information is not always available. We examined the accuracy of claims-based definitions of incident cancers and their date of diagnosis... - Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin useM Alan Brookhart
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass, USA
Arch Intern Med 167:847-52. 2007.... - Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritisSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
Arthritis Rheum 56:1754-64. 2007..To assess the association between the initiation of anti-tumor necrosis factor alpha (anti-TNFalpha) therapy and the risk of serious bacterial infections in routine care... - Repeated hospitalizations predict mortality in the community population with heart failureSoko Setoguchi
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02130, USA
Am Heart J 154:260-6. 2007..The impact of repeated heart failure (HF) hospitalization on mortality has not been studied for a large community population with HF. We aimed to characterize survival of patients in relation to the number of HF hospitalizations... - Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysisNiteesh K Choudhry
Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts, USA
Health Aff (Millwood) 26:186-94. 2007..Our analysis suggests that covering combination therapy for such patients will save both lives and money... - Statins and the risk of lung, breast, and colorectal cancer in the elderlySoko Setoguchi
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, MA 02130, USA
Circulation 115:27-33. 2007..Long-term statin users tend to be healthier, less frail, and more adherent to therapy than nonusers, however. This could explain such apparent "protective" effects... - Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritisDaniel H Solomon
Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
Arthritis Rheum 54:3790-8. 2006..This study was undertaken to investigate the effects of various immunosuppressive medications on the risk of cardiovascular events among a group of older patients with RA... - Angiotensin inhibition after myocardial infarction: does drug class matter?Wolfgang C Winkelmayer
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02120, USA
J Gen Intern Med 21:1242-7. 2006..Little is known about their relative use after MI in typical care settings, and about their relative effectiveness outside the clinical trial setting... - Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysisSebastian Schneeweiss
Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics, Boston, MA 021205, USA
Arthritis Rheum 54:3390-8. 2006.... - Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritisSoko Setoguchi
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02130, USA
Arthritis Rheum 54:2757-64. 2006..This study was undertaken to estimate the association between treatment with biologic disease-modifying antirheumatic drugs (DMARDs) and development of cancer in patients with RA... - Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthmaColin R Dormuth
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
Clin Ther 28:964-78; discussion 962-3. 2006..Evaluations of drug cost-sharing policies within the same population are needed for a fair comparison of different options... - Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimalGabriela Schmajuk
Stanford University, Palo Alto, California, USA
Arthritis Rheum 57:928-34. 2007..Our objective was to determine the rate and predictors of DMARD use in a cohort of elderly patients with RA... - Analysis of factors associated with statin adherence in a hierarchical model considering physician, pharmacy, patient, and prescription characteristicsAlexander Pedan
Analytical Services, Adheris, Inc, One Van de Graaff Dr, Burlington, MA 01803, USA
J Manag Care Pharm 13:487-96. 2007..Adherence with maintenance drug therapy such as HMG-CoA reductase inhibitors (statins) is typically analyzed from the perspective of patient characteristics... - Adherence to beta-blocker therapy under drug cost-sharing in patients with and without acute myocardial infarctionSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont St Ste 3030, Boston, MA 02120, USA
Am J Manag Care 13:445-52. 2007.... - Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groupsDaniel H Solomon
Brigham and Women s Hospital, 1620 Tremont Street, Boston, MA 02120, USA
Arthritis Rheum 59:1097-104. 2008..There is substantial concern regarding the potential cardiovascular adverse effects of selective coxibs and nonselective NSAIDs, but many patients with arthritis experience important clinical benefits from these agents... - Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritisSoko Setoguchi
Divisions of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard MedicalSchool, Boston, MA 02130, USA
Am Heart J 156:336-41. 2008..Although TNFAs had significant benefits in treating rheumatoid arthritis (RA), little is known whether the drugs pose an increased risk of HF in older patients with RA... - Does knowledge of medication prices predict physicians' support for cost effective prescribing policiesJennifer M Polinski
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Boston, MA, USA
Can J Clin Pharmacol 15:e286-94. 2008..Years after implementation, these policies remain controversial among physicians... - Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medicationsColin R Dormuth
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
Clin Ther 30:1038-50. 2008..Objective: The aim of this study was to compare the effects of 2 recent cost-sharing policies on emergency hospitalizations due to chronic obstructive pulmonary disease, asthma, or emphysema (CAE), and on physician visits... - Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapiesNiteesh K Choudhry
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
Am Heart J 156:31-6. 2008..Removing patient out-of-pocket drug costs may increase adherence, improve clinical outcomes, and even reduce overall health costs for high-risk patients. The existing data are inadequate to assess whether this strategy is effective... - The risk of infection associated with tumor necrosis factor alpha antagonists: making sense of epidemiologic evidenceDaniel H Solomon
Brigham and Women's Hospital, Division of Rheumatology, Immunology and Allergy, and Harvard Medical School, Boston, Massachusetts 02115, USA
Arthritis Rheum 58:919-28. 2008 - The impact of cost sharing on antidepressant use among older adults in British ColumbiaPhilip S Wang
National Institute of Mental Health, Bethesda, MD 20892 9629, USA
Psychiatr Serv 59:377-83. 2008.... - Evaluating uses of data mining techniques in propensity score estimation: a simulation studySoko Setoguchi
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02130, USA
Pharmacoepidemiol Drug Saf 17:546-55. 2008.... - A cross-national study of the persistence of antihypertensive medication use in the elderlyBoris L G Van Wijk
Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands b l g
J Hypertens 26:145-53. 2008..The aim of this study was to describe and compare patterns of use of antihypertensive drugs in a population of elderly patients in the United States (Pennsylvania), Canada (British Columbia) and the Netherlands... - Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medicationsPhilip S Wang
J Clin Psychopharmacol 27:707-10. 2007 - Designed delays versus rigorous pragmatic trials: lower carat gold standards can produce relevant drug evaluationsMalcolm Maclure
School of Health Information Science, University of Victoria, Victoria, British Columbia, Canada
Med Care 45:S44-9. 2007..Centralized administrative databases enable low-cost pragmatic randomized trials (PRTs) of drug effectiveness and safety. We simplified the PRT strategy by using designed delays (DD) to evaluate drug policies... - Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial resultsSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
Med Care 45:S131-42. 2007..The goal of restricting study populations is to make patients more homogeneous regarding potential confounding factors and treatment effects and thereby achieve less biased effect estimates... - Evaluating the validity of an instrumental variable study of neuroleptics: can between-physician differences in prescribing patterns be used to estimate treatment effects?M Alan Brookhart
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, Massachusetts, USA
Med Care 45:S116-22. 2007..We sought to explore the validity of physician-level IV in a comparative study of short-term mortality risk among elderly users of conventional versus atypical antipsychotic medications (APM)... - Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: a policy reviewMichael A Fischer
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Boston, MA 02120, USA
Med Care 44:658-63. 2006..However, the evidence base for the prior authorization criteria has not been examined previously... - Assessing health state utilities in elderly patients at cardiovascular riskWolfgang C Winkelmayer
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
Med Decis Making 26:247-54. 2006..Health state preferences can be a crucial component of cost-effectiveness analyses, but off-the-shelf health state utilities specifically for older people are not available... - Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of riskDaniel H Solomon
Division of Pharmacoepidemiology, Brigham and Women s Hospital, Boston, Massachusetts 02120, USA
Arthritis Rheum 54:1378-89. 2006..This study was undertaken to examine, in a large group of new users of coxibs and NSAIDs, the rate of cardiovascular events, their time course, and whether baseline cardiovascular risk modified the rate ratios (RRs) for future events... - Consistency of performance ranking of comorbidity adjustment scores in Canadian and U.S. utilization dataSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics, Gigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
J Gen Intern Med 19:444-50. 2004..We sought to evaluate and rank the performance of comorbidity scores across selected U.S. and Canadian elderly populations using health care utilization databases... - Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adultsDaniel H Solomon
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, Mass 02120, USA
Circulation 109:2068-73. 2004..We studied the relative risk of acute myocardial infarction (AMI) among users of celecoxib, rofecoxib, and NSAIDs in Medicare beneficiaries with a comprehensive drug benefit... - Use of the case-crossover design to study prolonged drug exposures and insidious outcomesPhilip S Wang
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Ann Epidemiol 14:296-303. 2004..We investigated whether case-crossover methods can be used to study prolonged exposures and insidious outcomes... - Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluationsSebastian Schneeweiss
Brigham and Women s Hospital and Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics, 1620 Tremont St Suite 3030, Boston, MA 02120, USA
BMJ 328:560. 2004..To compare the results of a randomised and an observational evaluation of the same policy that restricted reimbursement for nebulised respiratory medications in adult patients in a community setting... - Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important?Daniel H Solomon
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Am J Med 115:715-20. 2003..We examined the relative effects of patient risk factors for gastrointestinal toxicity, other patient characteristics, and physician prescribing preferences on the decision to prescribe a selective COX-2 inhibitor... - Improved comorbidity adjustment for predicting mortality in Medicare populationsSebastian Schneeweiss
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Health Serv Res 38:1103-20. 2003..80. CONCLUSIONS: We conclude that in epidemiologic studies of the elderly, a modified diagnosis-based score using empirically derived weights provides improved adjustment for comorbidity and enhances the validity of findings... - Physician gender and changes in drug prescribing after the implementation of reference pricing in British ColumbiaMargreet S Duetz
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
Clin Ther 25:273-84. 2003..However, these differences are unlikely to have meaningful clinical or economic consequences... - European healthcare policies for controlling drug expenditureSilvia M Ess
Hirslanden Research, Zurich, Switzerland
Pharmacoeconomics 21:89-103. 2003..Policies intended to affect physicians' prescribing behaviour include guidelines, information (about price and less expensive alternatives) and feedback, and the use of budgetary restrictions... - Metric properties of the appropriateness evaluation protocol and predictors of inappropriate hospital use in Germany: an approach using longitudinal patient dataOliver Sangha
Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
Int J Qual Health Care 14:483-92. 2002..Time since admission was the strongest predictor of inappropriate hospital use adjusted for length of stay, comorbidity, age, and gender... - Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trialJerry Avorn
Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
Control Clin Trials 23:757-73. 2002.... - Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy complianceSebastian Schneeweiss
Divison of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 221 Longwood Ave BLI 341, Boston, MA 02115, USA
J Clin Epidemiol 55:833-41. 2002..Results from nonrandomized comparisons of subgroups defined by their compliance to a policy change should generally be interpreted cautiously, and several biases should be explored... - Clozapine use and risk of diabetes mellitusPhilip S Wang
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
J Clin Psychopharmacol 22:236-43. 2002..Additional data from pharmacoepidemiologic studies and randomized controlled trials are needed to exclude the possibility of residual confounding and ensure the appropriate use of this agent... - Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilizationSebastian Schneeweiss
Department of Epidemiology, Harvard School of Public Health, Boston, Mass, USA
CMAJ 166:737-45. 2002..The objective of this study was to analyze the effect of reference-based pricing of angiotensin-converting enzyme (ACE) inhibitors on drug utilization, cost savings and potential substitution with other medication classes... - Prescription duration after drug copay changes in older people: methodological aspectsSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, 221 Longwood Ave, Boston, MA 02115, USA
J Am Geriatr Soc 50:521-5. 2002..Reference pricing, a copayment for expensive medications above a fixed limit, for angiotensin-converting enzyme(ACE) inhibitors in older British Columbia residents, is used as a case example... - Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residentsSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA
Med Care 42:653-60. 2004..Critics argued that drug plan savings are offset by administrative costs and increased spending on other health services... - Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital recordsYuka Kiyota
Division of Pharmacoepidemiology and Pharmacoeconomics, Boston, Mass USA
Am Heart J 148:99-104. 2004..1% vs 94.6%, P <.001). CONCLUSIONS: In this study, we observed high positive predictive values for a Medicare claims-based diagnosis of AMI and a diagnosis based on structured hospital record review... - Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variableM Alan Brookhart
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, MA 02120, USA
Epidemiology 17:268-75. 2006..Instrumental variable methods have been proposed as a potential approach to control confounding by indication in nonexperimental studies of treatment effects; however, good instruments are hard to find... - Measuring prescribing improvements in pragmatic trials of educational tools for general practitionersMalcolm Maclure
School of Health Information Science, Faculty of Human and Social Development, University of Victoria, British Columbia BC, Canada
Basic Clin Pharmacol Toxicol 98:243-52. 2006..A decade of progress on methods for evaluating prescribing improvement programs with drug claims data has enabled planning of routine randomized pragmatic trials of education and policies in primary care in Canada... - A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequencesSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
Clin Pharmacol Ther 79:379-88. 2006..We evaluated the clinical and economic consequences of coverage restriction for 3 leading proton pump inhibitors (PPIs) in a large-scale natural experiment... - Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetesWolfgang C Winkelmayer
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
Am J Kidney Dis 46:1080-7. 2005..However, little is known about the adequacy of adherence to these guidelines in elderly patients with diabetes and predictors of such appropriate ACE-inhibitor or ARB use... - Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic modelRoy H Perlis
Pharmacogenomics Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
J Clin Psychopharmacol 25:427-34. 2005..More consistent reporting of test parameters such as sensitivity and specificity would greatly facilitate assessment of future pharmacogenetic studies... - Performance of a rheumatoid arthritis records-based index of severityGladys Ting
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
J Rheumatol 32:1679-87. 2005..Further tests of the RARBIS are recommended before it can be used as a tool to adjust for RA disease severity in performing epidemiologic studies on the safety of drugs... - Identification of individuals with CKD from Medicare claims data: a validation studyWolfgang C Winkelmayer
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
Am J Kidney Dis 46:225-32. 2005..The validity of this approach to identify patients with CKD has not been sufficiently studied... - Sudden uncontrollable somnolence and medication use in Parkinson diseaseJerry Avorn
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
Arch Neurol 62:1242-8. 2005.... - Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensivesPhilip S Wang
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
Hypertension 46:273-9. 2005..Highly prevalent, noncardiovascular conditions appear to deter use of antihypertensives in elderly with hypertension... - A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitorsSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
J Clin Epidemiol 58:98-102. 2005..We sought to quantify the relative contributions of patient vs. physician factors to the decision to prescribe selective cyclooxygenase-2 (COX-2) inhibitors during the first 2 years of their availability... - Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarctionSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
Epidemiology 16:17-24. 2005..We show how to assess the impact of confounding by factors not measured in Medicare claims data in a study of the association between selective COX2 inhibitors and acute myocardial infarction (MI)... - Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitorsMichael A Fischer
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
N Engl J Med 351:2187-94. 2004..To control these expenses, many state Medicaid programs have implemented prior-authorization requirements before coxibs can be prescribed. We evaluated the effect of such programs on the use of coxibs by Medicaid beneficiaries... - Therapeutic delay and reduced functional status six months after thrombolysis for acute myocardial infarctionJerry Avorn
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, 1620 Tremont Street, Boston, MA 02120, USA
Am J Cardiol 94:415-20. 2004..Thus, in patients with AMI, earlier presentation to the hospital and more rapid initiation of thrombolysis could prevent significant decreases in functional status months after the initial infarct... - Relationship between COX-2 specific inhibitors and hypertensionDaniel H Solomon
Division of Pharmacoepidemiology, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02120, USA
Hypertension 44:140-5. 2004..1; 95% CI, 1.0 to 4.3). In this retrospective case-control study of patients aged > or =65 years, rofecoxib use was associated with an increased relative risk of new onset hypertension; this was not seen in patients taking celecoxib... - Outcomes of reference pricing for angiotensin-converting-enzyme inhibitorsSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
N Engl J Med 346:822-9. 2002..Although reference pricing may reduce the costs of prescription drugs, there is concern that patients may switch to less effective medications or stop treatment...
Research Grants
- Impact of Medicare Drug Coverage on Antidepressant Quality and OutcomesSebastian Schneeweiss; Fiscal Year: 2007..g., to formulary, cost-sharing, and MTM programs) be made to improve the quality and outcomes of pharmacotherapies in susceptible and traditionally under-served elderly with depression. ..
- Antidepressant Use and Suicidality: Comparative Safety in Children and AdultsSebastian Schneeweiss; Fiscal Year: 2007....
- Consequences of Drug Cost Sharing:A New Randomized TrialSebastian Schneeweiss; Fiscal Year: 2006..It should further provide a set of refined tools describing how to plan, implement, and execute drug cost-saving measures, including a pre-policy impact-simulation software. ..
- Effects of income-based drug charges on older PatientsSebastian Schneeweiss; Fiscal Year: 2006..abstract_text> ..
- CONSEQUENCES OF DRUG COST SHARING IN THE ELDERLYSebastian Schneeweiss; Fiscal Year: 2002..Additional analyses will examine possible changes in prescribing patterns for persons initiating ACEI or CCB treatment. ..
- Analyzing Complex Healthcare Data to Determine Causality of Observed Drug EffectsSEBASTIAN G SCHNEEWEISS; Fiscal Year: 2010..The theoretical foundation and the ready-to-use algorithms will likely lead to a fundamental shift in how databases contribute to the fast and accurate assessment of newly-marketed medications. ..